S CONFERENCE Highlights included:
elivery systems including the oral preparation, Paltusotine, a once daily oral SSA, e I/II study in those with Carcinoid Syndrome (NCT05361668) - showing evidence in ur effect. EBIO 4126 is a novel intra-muscular injection of 3 month extended release Octreotide XTEND-01 trial is due complete this December. injection - this study is to compare the effectiveness and safety of CAM2029 to octreotide d GEP-NET: the SORENTO trial is due to complete this December. egaly in the 2010s but yet to be assessed in NETs...or to be made commercially available). py. been a number of studies looking at combination regimens as maintenance treatment
izumab to standard chemotherapy treatment for advanced or metastatic neuroendocrine
b and sintilimab can further improve the effective rate and survival time of first-line ma (nb incl G3 NET). astatic NEC With Pulmonary or Gastroenteropancreatic Origin. O READ MORE), and SENECA. nb FOLFIRI remains a good control arm (standard) for
ay not be enough: a perspective study will look at chemotherapy (eg FOLFIRI) vs
n more than 50% of NECs: p people with small cell lung cancer or other neuroendocrine cancers with expression of DLL3 - Other potential targets are being explored. ril - check HERE for further details and how to register - or visit our YouTube channel after
Made with FlippingBook flipbook maker